Physician profile
Scott Kaple
NPI 1144318551
$5,628.65
in general payments reported to CMS, 2019-2025
33 companies · $85.54 in 2025
The $85.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,209 · 2020: $1,657 · 2021: $963 · 2022: $299 · 2023: $274 · 2024: $141 · 2025: $85.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,364.22 | 2019-2022 | |
| Amgen INC. | $543.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $526.45 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.02 | 2022-2025 | |
| Pfizer INC. | $359.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $336.05 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $309.72 | 2019-2021 | |
| Astellas Pharma US INC | $195.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.57 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $140.51 | 2024 | Voquezna |
| Lilly USA, LLC | $132.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $128.27 | 2020-2021 | |
| Amarin Pharma, INC. | $105.06 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $99.88 | 2020 | |
| Vanda Pharmaceuticals INC. | $97.51 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93.62 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $91.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $89.34 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.49 | 2019-2021 | |
| Allergan, INC. | $83.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $71.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.81 | 2019-2021 | |
| Abbott Laboratories | $23.80 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.25 | 2021 | |
| Scilex Pharmaceuticals INC. | $20.35 | 2019 | |
| Mannkind Corporation | $16.85 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.17 | 2019 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.56 | 2021 | |
| Lundbeck LLC | $14.54 | 2020 | |
| Alnylam Pharmaceuticals INC. | $11.77 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.08 | 2020 | |
| Medtronic Minimed, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kaple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.